Table 1.
Patient characteristics
| N (%) | |
|---|---|
| Total cases (≥2 years) | 4166 (100) |
| Age (years) | |
| 2 to 5 | 836 (20.1) |
| 6 to 12 | 1681 (40.4) |
| >12 | 1649 (39.6) |
| Gender | |
| male | 2562 (61.5) |
| female | 1604 (38.5) |
| Race | |
| white | 2539 (60.9) |
| African American | 786 (18.9) |
| Hispanic | 577 (13.9) |
| other | 257 (6.2) |
| Primary diagnosis | |
| obstructive uropathy | 837 (20.1) |
| focal segmental glomerulosclerosis | 478 (11.5) |
| renal dysplasia | 529 (12.7) |
| reflux nephropathy | 389 (9.3) |
| other | 1833 (44.0) |
| Anemia | |
| hematocrit ≥33% | 2589 (62.1) |
| hematocrit <33% | 1577 (37.9) |
| CKD stage | |
| stage II | 828 (19.9) |
| stage III | 2162 (51.9) |
| stage IV | 1176 (28.2) |
| CRI registry year | |
| before 2000 | 2795 (67.1) |
| 2000 and after | 1371 (32.9) |
| Erythropoietin use | |
| yes | 557 (13.4) |
| no | 3606 (86.6) |
| Growth hormone use | |
| yes | 281 (6.7) |
| no | 3878 (93.1) |
| Calcium (corrected) | |
| low | 214 (5.1) |
| normal | 2728 (65.5) |
| high | 632 (15.2) |
| Phosphorus | |
| normal | 2654 (63.7) |
| elevated | 1177 (28.3) |
| Parathyroid hormone | |
| <2× upper limit | 1477 (35.5) |
| >2× upper limit | 853 (20.5) |
| unknown | 1836 (44.1) |
| Iron supplementation | |
| yes | 997 (23.9) |
| no | 3157 (75.8) |
| Anti-hypertensive medication use | |
| yes | 1928 (46.3) |
| no | 2230 (53.5) |
| Albumin | |
| ≤4.0 g/dl | 1954 (46.9) |
| >4.0 g/dl | 1674 (40.2) |
| Hypertension | |
| yes | 1954 (46.9) |
| no | 2154 (51.7) |
Percents may not total 100% because of missing values.